miRNA Oligonucleotide Therapeutics with Active Targeting for Cardio-Metabolic Diseases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and related cardiometabolic disorders, such as NAFLD/NASH/MAFLD, are ineffective in achieving long-term weight reduction and are associated with significant side effects and high costs.
Innovation Solution
Development of novel compositions comprising miRNA agomirs and antagomirs that target specific miRNAs involved in lipid oxidation, mitochondrial activity, energy expenditure, fat accumulation, inflammation, and necrosis, combined with targeting elements like fatty acid translocase (FAT) to facilitate active targeted delivery to adipocytes and metabolic organs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current obesity treatments are used, then weight reduction is achieved, but long-term adherence is poor and therapeutic goals are not met
Solution Approach 1:
The patent segments the delivery system into multiple components: ONT therapeutic agents, targeting elements, and delivery vehicles. This segmentation allows for optimized delivery to specific tissues (adipocytes, liver, muscle) while maintaining systemic circulation, improving long-term efficacy through targeted action rather than non-specific weight loss approaches
Solution Approach 2:
The patent introduces targeting elements (such as antibodies, peptides, or aptamers) as intermediaries that bridge the ONT therapeutic agents to specific cell surfaces. These intermediaries facilitate active targeting and enhance delivery efficiency to metabolic organs, ensuring sustained therapeutic effect and improving long-term goal achievement
2Productivity
If current obesity drugs are administered, then some weight loss is achieved, but side effects and safety issues arise
Solution Approach 1:
The patent applies local quality by designing ONT formulations with specific targeting elements that concentrate the therapeutic effect in metabolic organs (adipose tissue, liver, skeletal muscle) while minimizing systemic exposure. This localized action reduces off-target effects and safety issues associated with non-specific weight loss drugs
Solution Approach 2:
The patent uses ONT agents that replicate or mimic natural miRNA functions in a controlled manner, allowing precise regulation of metabolic pathways without the harmful side effects of conventional drugs. The ONTs copy the natural regulatory role of miRNAs to achieve weight loss through physiological mechanisms rather than synthetic drug action
3Productivity
If bariatric surgery is performed, then significant weight reduction is achieved, but chronic digestive malabsorption is created
Solution Approach 1:
The patent replaces the mechanical intervention of bariatric surgery with a pharmacological approach using ONT agents. This substitution achieves weight reduction through molecular mechanisms (miRNA regulation) rather than physical restriction or malabsorption, avoiding the creation of chronic digestive malabsorption while maintaining significant weight excess reduction
4Reliability
If miRNA ONT agents are developed, then targeted delivery to adipocytes is achieved, but delivery efficiency to metabolic organs is limited
Solution Approach 1:
The patent designs ONT formulations with multi-functional targeting elements that can simultaneously target multiple metabolic organs (adipocytes, liver, skeletal muscle) while maintaining high delivery efficiency to each. This universal approach ensures both reliable targeted delivery and high productivity across multiple tissues, overcoming the limitation of single-target specificity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution minimizes systemic exposure and off-target effects, improving the therapeutic index, reducing costs, and enhancing patient adherence and convenience, while achieving significant metabolic benefits.
Implementation Method 1
targeting elements (e.g., molecules transported by the cellular membrane transporter Fatty Acid Translocase (FAT)) that facilitate cellular uptake and delivery of the miRNA agomirs and/or antagomirs inside the targeted adipocytes and/or metabolic organs
Data Source
AI summary
Disclosed herein are novel methods and compositions for treatment of obesity and/or related cardio-metabolic disorders such as dyslipidemia, Type 2 diabetes mellitus, NASH, NAFLD, and/or MAFLD. In some embodiments, compositions may include a) a miRNA antagomir or agomir oligonucleotide therapeutic (ONT) agent capable of modulating lipid oxidation, mitochondrial activity, energy expenditure, fat accumulation, inflammation, and/or necrosis, and b) a targeting element facilitating cellular uptake and delivery of a miRNA ONT agent to targeted adipocytes and metabolic organs.